DK2091949T3 - Indolderivater som S1P1-receptor agonister - Google Patents
Indolderivater som S1P1-receptor agonisterInfo
- Publication number
- DK2091949T3 DK2091949T3 DK07857808.5T DK07857808T DK2091949T3 DK 2091949 T3 DK2091949 T3 DK 2091949T3 DK 07857808 T DK07857808 T DK 07857808T DK 2091949 T3 DK2091949 T3 DK 2091949T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptor agonists
- indole derivatives
- indole
- derivatives
- agonists
- Prior art date
Links
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000002475 indoles Chemical class 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0625647A GB0625647D0 (en) | 2006-12-21 | 2006-12-21 | Compounds |
| GB0707615A GB0707615D0 (en) | 2007-04-19 | 2007-04-19 | Compounds |
| PCT/EP2007/064185 WO2008074821A1 (en) | 2006-12-21 | 2007-12-19 | Indole derivatives as s1p1 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2091949T3 true DK2091949T3 (da) | 2011-07-18 |
Family
ID=39283563
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07857808.5T DK2091949T3 (da) | 2006-12-21 | 2007-12-19 | Indolderivater som S1P1-receptor agonister |
| DK10158582.6T DK2206710T3 (da) | 2006-12-21 | 2007-12-19 | Indolderivater som s1p1-receptor agonister |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10158582.6T DK2206710T3 (da) | 2006-12-21 | 2007-12-19 | Indolderivater som s1p1-receptor agonister |
Country Status (32)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5099005B2 (ja) | 2006-04-03 | 2012-12-12 | アステラス製薬株式会社 | ヘテロ化合物 |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| EA016443B1 (ru) | 2007-04-19 | 2012-05-30 | Глэксо Груп Лимитед | Оксадиазолзамещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (s1p) |
| GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
| ES2549761T3 (es) | 2008-05-14 | 2015-11-02 | The Scripps Research Institute | Nuevos moduladores de los receptores de esfingosina fosfato |
| WO2009151626A1 (en) * | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| WO2009151621A1 (en) * | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| UY31922A (es) * | 2008-06-20 | 2010-01-05 | Glaxo Group Ltd | Compuestos |
| KR20220084423A (ko) | 2008-07-23 | 2022-06-21 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체 |
| KR101608108B1 (ko) * | 2008-07-23 | 2016-03-31 | 노파르티스 아게 | 스핑고신 1 포스페이트 수용체 조절제 및 근육 염증을 치료하기 위한 그의 용도 |
| HUE031479T2 (en) | 2008-08-27 | 2017-07-28 | Arena Pharm Inc | Substituted tricyclic acid derivatives as S1P1 receptor agonists that can be used in the treatment of autoimmune and inflammatory disorders. |
| MX2011006560A (es) * | 2008-12-18 | 2011-08-03 | Merck Serono Sa | Derivados heterociclicos fucionados con oxadiazola utiles para el tratamiento de esclerosis multiple. |
| EP2202232A1 (en) * | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| EP2241558A1 (en) * | 2009-04-03 | 2010-10-20 | Merck Serono SA | Oxadiazole derivatives |
| GB0910689D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| GB0910667D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| WO2011005295A1 (en) * | 2009-06-24 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto |
| UA107360C2 (en) * | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| CA2780772C (en) | 2009-11-13 | 2018-01-16 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| EP2513095A4 (en) * | 2009-12-18 | 2013-05-15 | Glaxo Group Ltd | OXADIAZOLSUBSTITUTED INDAZONE DERIVATIVES FOR USE AS SPHINGOSIN-1-PHOSPHATE-1 (S1P1) RECEPTOR AGONISTS |
| JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| JP2013521301A (ja) * | 2010-03-03 | 2013-06-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１ｐ１受容体修飾物質およびその結晶形の調製のためのプロセス |
| WO2011133734A1 (en) | 2010-04-23 | 2011-10-27 | Bristol-Myers Squibb Company | 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists |
| EP2619190B1 (en) | 2010-09-24 | 2015-08-12 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| ME02556B (me) | 2011-02-07 | 2017-02-20 | Biogen Ma Inc | Agensi koji moduliraju s1 p |
| JP6129159B2 (ja) | 2011-05-13 | 2017-05-17 | レセプトス エルエルシー | 選択的複素環式スフィンゴシン１−リン酸受容体モジュレーター |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| GB201202027D0 (en) * | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| PT3310760T (pt) | 2015-06-22 | 2022-11-10 | Arena Pharm Inc | Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1 |
| ES2877686T3 (es) * | 2016-07-22 | 2021-11-17 | Shijiazhuang Sagacity New Drug Dev Co Ltd | Agonista S1P1 y aplicación del mismo |
| WO2018064356A1 (en) | 2016-09-29 | 2018-04-05 | Celgene International Ii Sarl | Compounds and methods for treating lupus |
| MX2019009843A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales. |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| AU2019280822A1 (en) | 2018-06-06 | 2021-01-07 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| CN110627778B (zh) * | 2018-06-25 | 2023-01-24 | 中国科学院上海药物研究所 | 一类含有1,2,4-噁二唑环的化合物、其制备方法及其在免疫抑制药物中的应用 |
| CN119751336A (zh) | 2018-09-06 | 2025-04-04 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
| CN114599363A (zh) | 2019-10-31 | 2022-06-07 | 爱杜西亚药品有限公司 | Cxcr7拮抗剂与s1p1受体调节剂的组合 |
| ES2964482T3 (es) | 2019-12-03 | 2024-04-08 | Lg Chemical Ltd | Agonista del receptor de esfingosina-1-fosfato, método de preparación del mismo y composición farmacéutica que comprende el mismo como agente activo |
| EP4103549A1 (en) * | 2020-02-11 | 2022-12-21 | Syngenta Crop Protection AG | Pesticidally active cyclic amine compounds |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| WO2025083549A1 (en) | 2023-10-16 | 2025-04-24 | Sun Pharma Advanced Research Company Limited | Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3939238A1 (de) | 1989-11-28 | 1991-05-29 | Bayer Ag | Heterocyclisch substituierte acrylsaeureester |
| DE4002466A1 (de) | 1990-01-28 | 1991-10-10 | Bayer Ag | Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester |
| US5523312A (en) | 1994-09-27 | 1996-06-04 | Sterling Winthrop Inc. | Antipicornaviral agents |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19643037A1 (de) | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| WO2004103279A2 (en) | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| EP1479675A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
| US20070043014A1 (en) * | 2003-10-01 | 2007-02-22 | Merck & Co., Inc. | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| AU2004299456B2 (en) | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| EP1760071A4 (en) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
| CA2583681A1 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
| WO2006090817A1 (ja) | 2005-02-25 | 2006-08-31 | Ono Pharmaceutical Co., Ltd. | インドール化合物およびその用途 |
| ES2316062T3 (es) | 2005-03-23 | 2009-04-01 | Actelion Pharmaceuticals Ltd. | Derivados novedosos de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1. |
| NZ563522A (en) | 2005-04-22 | 2010-01-29 | Daiichi Sankyo Co Ltd | Heterocyclic compound with immunosuppressive activity |
| BRPI0612028A2 (pt) | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
| AU2006283175A1 (en) | 2005-08-23 | 2007-03-01 | Irm Llc | Immunosuppressant compounds and compositions |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| JP2007262009A (ja) | 2006-03-29 | 2007-10-11 | Dai Ichi Seiyaku Co Ltd | ヘテロアリール低級カルボン酸誘導体 |
| JP5099005B2 (ja) * | 2006-04-03 | 2012-12-12 | アステラス製薬株式会社 | ヘテロ化合物 |
| BRPI0716171B8 (pt) | 2006-09-07 | 2021-05-25 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica e uso de um composto |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| EA016443B1 (ru) * | 2007-04-19 | 2012-05-30 | Глэксо Груп Лимитед | Оксадиазолзамещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (s1p) |
-
2007
- 2007-12-17 JO JO2007554A patent/JO2701B1/en active
- 2007-12-19 WO PCT/EP2007/064185 patent/WO2008074821A1/en not_active Ceased
- 2007-12-19 AT AT07857808T patent/ATE509927T1/de active
- 2007-12-19 MY MYPI20092612A patent/MY148470A/en unknown
- 2007-12-19 US US12/520,145 patent/US8101775B2/en not_active Expired - Fee Related
- 2007-12-19 AU AU2007336224A patent/AU2007336224B2/en not_active Ceased
- 2007-12-19 CA CA2673468A patent/CA2673468C/en not_active Expired - Fee Related
- 2007-12-19 SI SI200731001T patent/SI2206710T1/sl unknown
- 2007-12-19 BR BRPI0721127-9A patent/BRPI0721127A2/pt not_active IP Right Cessation
- 2007-12-19 HR HR20110456T patent/HRP20110456T1/hr unknown
- 2007-12-19 MY MYPI2012004367A patent/MY156822A/en unknown
- 2007-12-19 SG SG2011095114A patent/SG177914A1/en unknown
- 2007-12-19 PL PL10158582T patent/PL2206710T3/pl unknown
- 2007-12-19 AR ARP070105729A patent/AR064452A1/es unknown
- 2007-12-19 EP EP10158582A patent/EP2206710B1/en active Active
- 2007-12-19 CN CN201210396720.5A patent/CN103012390B/zh not_active Expired - Fee Related
- 2007-12-19 JP JP2009542043A patent/JP5309034B2/ja not_active Expired - Fee Related
- 2007-12-19 ES ES10158582T patent/ES2389879T3/es active Active
- 2007-12-19 SI SI200730670T patent/SI2091949T1/sl unknown
- 2007-12-19 EP EP07857808A patent/EP2091949B1/en active Active
- 2007-12-19 DK DK07857808.5T patent/DK2091949T3/da active
- 2007-12-19 NZ NZ577387A patent/NZ577387A/en not_active IP Right Cessation
- 2007-12-19 EA EA200970612A patent/EA017406B1/ru not_active IP Right Cessation
- 2007-12-19 KR KR1020097012841A patent/KR101495927B1/ko not_active Expired - Fee Related
- 2007-12-19 TW TW096148543A patent/TWI393564B/zh not_active IP Right Cessation
- 2007-12-19 PT PT07857808T patent/PT2091949E/pt unknown
- 2007-12-19 DK DK10158582.6T patent/DK2206710T3/da active
- 2007-12-19 PT PT10158582T patent/PT2206710E/pt unknown
- 2007-12-19 PL PL07857808T patent/PL2091949T3/pl unknown
- 2007-12-19 MX MX2009006882A patent/MX2009006882A/es active IP Right Grant
- 2007-12-20 CL CL200703755A patent/CL2007003755A1/es unknown
-
2008
- 2008-01-02 PE PE2012000146A patent/PE20121076A1/es not_active Application Discontinuation
- 2008-01-02 PE PE2008000023A patent/PE20081398A1/es not_active Application Discontinuation
-
2009
- 2009-06-04 IL IL199187A patent/IL199187A/en not_active IP Right Cessation
- 2009-06-05 DO DO2009000133A patent/DOP2009000133A/es unknown
- 2009-06-17 MA MA32003A patent/MA30999B1/fr unknown
- 2009-06-23 NO NO20092385A patent/NO20092385L/no not_active Application Discontinuation
- 2009-07-13 CR CR10922A patent/CR10922A/es unknown
-
2011
- 2011-07-19 CY CY20111100700T patent/CY1111702T1/el unknown
-
2012
- 2012-08-29 HR HRP20120685TT patent/HRP20120685T1/hr unknown
- 2012-09-20 CY CY20121100862T patent/CY1113131T1/el unknown
-
2014
- 2014-07-01 CR CR20140316A patent/CR20140316A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2091949T3 (da) | Indolderivater som S1P1-receptor agonister | |
| DK2069322T3 (da) | THIOPHENDERIVATER SOM S1P1/EDG1-receptoragonister | |
| DK2125797T3 (da) | Aminopyridinderivater som s1p1/edg1-receptoragonister | |
| DK1863474T3 (da) | Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister | |
| DK1856110T3 (da) | Oxyindol derivater som 5HT4-receptor agonister | |
| DK2029549T3 (da) | Phenyl-pyrazol-derivater som ikke-steroide glucocoricoid-receptorligander | |
| IL192657A (en) | Theophenic history as 1edg / 1p1s receptor agonists | |
| DK1989196T3 (da) | Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister | |
| BRPI0715324A2 (pt) | Composto de indol | |
| DK2094658T3 (da) | Tetrahydrocyclopenta[B]indolforbindelser som androgenreceptormodulatorer | |
| DK2225231T3 (da) | Aminotriazolderivater som alx-agonister | |
| DK2195311T3 (da) | Pyridinderivater som S1P1/EDG1-receptormodulatorer | |
| DK2066669T3 (da) | Adenosinderivater som A2A-receptoragonister | |
| DK2144897T3 (da) | 8-Oxy-quinolinderivater som bradykinin B2-receptormodulatorer | |
| DK2069335T3 (da) | Pyridin-3-ylderivater som immunomoduleringsmidler | |
| IL198931A0 (en) | Benzamide derivatives as ep4 receptor agonists | |
| DK2094709T3 (da) | Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister | |
| EP2079466A4 (en) | SUBSTITUTED INDOLE COMPOUNDS | |
| DK2069310T3 (da) | Sulfonylpyrazolin-1-carboxamidin-derivater som 5-HT6-antagonister | |
| ATE549350T1 (de) | Neuropeptid-2-rezeptor-agonisten | |
| DK2049480T3 (da) | 2-arylindolderivater som mPGES-1-hæmmere | |
| DK2148873T3 (da) | 4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister | |
| DK2132185T3 (da) | Pyrimidinyl-piperaziner nyttige som dopamin-D3/D2-receptorligander | |
| DK1740583T3 (da) | Oxadiazolon-derivater som ppar-delta-agonister | |
| ATE527249T1 (de) | Indole |